Navigation Links
Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics
Date:12/20/2011

CAMBRIDGE, England, December 21, 2011 /PRNewswire/ --

Arecor Limited has entered into a collaboration agreement with Eli Lilly and Company to assess Arecor's advanced protein formulation technologies for possible use with Lilly's growing pipeline of biological-based drugs.  Under this agreement, Arecor will develop stable aqueous or higher concentration formulations of emerging protein and peptide drug candidates developed by Lilly.  In addition, Arecor will work with Lilly to potentially offer improved formulations of Lilly's existing therapeutic proteins in several therapeutic areas.  

Tom Saylor, CEO of Arecor, stated, "The next generation of protein and peptide therapeutics present significant formulation challenges. Arecor's stabilization tools may enable new products and presentations, which would otherwise not be possible, without additional processing or changes to standard manufacturing practices.  Lilly's strong support of innovation and emerging technologies offers Arecor the potential to apply Arecor's broad-ranging expertise in biomolecule stabilization to a leader in pharmaceutical application of the next generation of biologics."

Arecor is a pioneer in the stabilization of biologic molecules, a key challenge in the development of many therapeutic proteins, vaccines and diagnostics. Arecor Limited was established to provide formulation solutions to pharmaceutical and biotech companies developing proteins, vaccines and diagnostics based upon new insights into interactions between proteins and their immediate environment. Proteins and vaccines are often fragile entities, and stability can represent significant constraints in the development of new products and extending the use of existing products. Arecor has developed Arestat™, a patented set of tools for stabilization which address the main pathways of degradation. As a simple reformulation, Arestat™ can be readily incorporated into standard manufacturing practice, without covalent modification of the biologic and using excipients approved for the route of delivery. Arecor currently has active feasibility programs and licenses with many of the top pharmaceutical and biotech companies on a wide range of proteins and vaccines.

Contact:

Tom Saylor, CEO
tsaylor@arecor.com
Arecor Limited
2 Cambridge Science Park
Cambridge, UK
http://www.arecor.com


'/>"/>
SOURCE Arecor
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuse Science Announces the Launch of its Analgesic and Diabetic Oral Fuse Delivery (OFD) Research Project Platforms
2. Enlight Biosciences Forms New Partnerships with AstraZeneca and Novo Nordisk
3. Diablo Valley Oncology Performs Breast Intraoperative Radiation Procedure - First in the East Bay
4. Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
5. ArjoHuntleigh Forms New Division to Enhance the Quality Home Medical Care
6. Digital ArtForms Debuts iMedic3D, a Radically Different Approach to Radiology, at RSNA ‘11, and Announces the Addition of Dr. Eliot Siegel and Dr. David Kim to Its Advisory Board Members
7. Awarepoint Corporation and MEDITECH Collaborate to Integrate Technology Platforms
8. Mindray Introduces Enhancements for M Series Ultrasound Platforms at ASA
9. ContinuumRx Forms Healthcare Joint Venture with Mississippi Baptist Health Systems
10. Stereotaxis Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms
11. Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016 ARANZ Medical  Ltd ... healthcare sector, has been named the Coretex Hi-Tech Emerging Company ... Dr Bruce Davey , CEO of ARANZ ...  It,s really good to be recognised for the work we ... are used in 35 countries around the world from Sub-Saharan ...
(Date:5/24/2016)... 2016 The innovator of ... , s first dual therapy stent, introduces catheters ... OrbusNeich, a global company specializing in the provision ... include products to treat peripheral artery disease. The JADE™ ... devices for lower limb and arteriovenous (AV) fistula intervention. ...
(Date:5/24/2016)... -- Dutch surgeons have launched a ground-breaking medical app ... treat patients on a global scale. Medical professionals from ... and the US have already signed up for the ... a totally secure environment. Education  "Imagine a ... with a surgeon at Harvard to treat a bomb victim via ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 2016 , ... In 1980, Bill Howe opened AM/PM Sewer and Drains as ... vision to grow the company was built on a simple mission of providing qualified ... training and customer service. Over 35 years later, Bill Howe remains one of the ...
(Date:5/26/2016)... ... May 26, 2016 , ... TopConsumerReviews.com recently awarded ... products . , High blood pressure affects millions of people worldwide, and many ... can lead to heart disease, stroke, kidney disease, and hardening of the arteries. ...
(Date:5/26/2016)... ... 26, 2016 , ... Bunion Bootie is a great option for ... save. For a limited time only (offer expires May 31, 2016) customers can save ... by using the promo code "Memorial" at checkout. The more Bunion Booties purchased, the ...
(Date:5/25/2016)... ... May 25, 2016 , ... “We ... Managing Partner at HealthScape Advisors. “Brad brings significant experience advising healthcare provider clients ... system accelerates with the implementation of MACRA, we believe that continuing to add ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... in Central Michigan, has produced another video highlighting one of the many supplemental ... Arts class. Sensei Ed Taylor, a 5 th Degree Black Belt in the ...
Breaking Medicine News(10 mins):